LoQus23 Therapeutics Names Cyrus Mozayeni as Chair of the Board
Portfolio - People | Feb 18, 2025 | PR Newswire Cision LoQus23 Therapeutics
LoQus23 Therapeutics, a Cambridge-based biotechnology company, has named Dr. Cyrus Mozayeni as its new Chair of the Board of Directors. This appointment comes after a successful £35 million Series A funding round, and the company is now moving forward with developing small molecule drugs to treat Huntington’s disease and other similar genetic disorders. Dr. Mozayeni, who brings extensive experience in biotech corporate strategy and business development, is the CEO of Pheon Therapeutics and has a track record of successful funding rounds and strategic growth in the life sciences sector. LoQus23 is positioned at a pivotal moment as it advances its MSH3 inhibitor into clinical trials, with plans for further development of its scientific pipeline in treating triplet repeat expansion diseases. The company has established a platform for its innovative therapies and benefited from the support and investment of groups like Forbion, SV Health Investors' Dementia Discovery Fund, and Novartis Venture Fund.
Sectors
- Biotechnology
- Pharmaceuticals
- Healthcare
Geography
- United Kingdom – LoQus23 Therapeutics is headquartered in Cambridge, UK.
- United States – Huntington's disease, one of LoQus23's targets, affects a significant number of patients in the US.
Industry
- Biotechnology – This industry is relevant as LoQus23 Therapeutics is a company focused on developing biotechnological solutions for genetic disorders like Huntington’s disease.
- Pharmaceuticals – Relevant due to LoQus23's development of small molecule drugs targeting genetic diseases.
- Healthcare – This is pertinent since the activities of LoQus23 relate to developing treatments for neurodegenerative and genetic diseases.
Financials
- £35 million – Amount raised by LoQus23 in their Series A funding round in October 2024.
- $120 million – Amount raised by Pheon Therapeutics in a Series B financing round in May 2024.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| LoQus23 Therapeutics Ltd | Target company | Company | A biotech company developing treatments for Huntington’s disease and similar disorders. |
| Cyrus Mozayeni | Chair of the Board of Directors | People | An experienced biotech executive appointed as LoQus23's chair, bringing expertise in corporate strategy. |
| Pheon Therapeutics | Company related to Cyrus Mozayeni | Company | A leading ADC company where Dr. Mozayeni serves as CEO. |
| Atlas Venture | Former Launch pad for Cyrus Mozayeni | Company | Venture capital firm where Dr. Mozayeni was an Entrepreneur-in-Residence. |
| Forbion | Investor | Company | Led the Series A financing round for LoQus23. |
| SV Health Investors' Dementia Discovery Fund | Investor | Company | Existing investor in LoQus23. |
| Novartis Venture Fund | Investor | Company | Existing investor in LoQus23. |